Clinical significance of the transcription factor (SOX11) expression in the bone marrow of acute myeloid leukemia patients

Table 1 Clinical and laboratory data of the acute myeloid leukemia patients

Parameters		Frequency
Gender, n (%)	Male	61 (59.8)
	Female	41 (40.2)
Age (years)	mean ± SD	42.61 ± 14.7
	Median (IQR)	44 (18-78)
Hb (g/dL)	mean ± SD	7.7 ± 2.1
Platelets (× 109/L)	Median (IQR)	46.5 (4-836)
TLC (× 109/L)	Median (IQR)	37.62 (11.2-488.9)
PB blast	Median (IQR)	30 (0-99)
BM blast	Median (IQR)	49 (0-98)
D14 blasts	Median (IQR)	0 (0-80)
D28 blasts	Median (IQR)	0 (0-80)
BM cellularity, n (%)	Hypocellular	11 (10.8)
	Normocellular	26 (25.5)
	Hypercellular	65 (63.7)
FAB, n (%)	AML-M0	2 (2)
	AML-M1	16 (15.7)
	AML-M2	44 (43.1)
	AML-M3	4 (3.9)
	AML-M4	28 (27.5)
	AML-M5	7 (6.9)
	AML-M6	1 (1.0)
CD34, n (%)	Negative	61 (60)
	Positive	41 (40)
Cytogenetics, n (%)	Normal	65 (64)
	Abnormal	37 (36)
Cytogenetics abnormalities, n (%)	Inv 16	9 (8.8)
	t (8;21)	16 (15.7)
	t (15;17)	4 (3.9)
	46xy, del7	4 (3.9)
	46xy, del 8, del 9	1 (1)
	46xy, +8	3 (42.9)
Molecular genetics markers, n (%)
FLT3 ITD, n (%)	Negative	65 (63.7)
	Positive	37 (36.3)
NPM, n (%)	Negative	71 (69.6)
	Positive	31 (30.4)
Response to induction therapy, n (%)	CR	33 (73.3)
	No CR	12 (26.7)
Relapse/refractory, n (%)	Negative	37 (72.5)
	Positive	14 (27.5)
Death, n (%)	Negative	31 (30.4)
	Positive	71 (69.6)
Liver, n (%)	Negative	87 (85.3)
	Positive	15 (14.7)
Spleen, n (%)	Negative	84 (82.4)
	Positive	18 (17.6)
LNs affection, n (%)	Negative	93 (91.2)
	Positive	9 (8.8)

BM: Bone marrow; CR: Complete remission; Hb: Hemoglobin; LNs: Lymph nodes; PB: Peripheral blood; TLC: Total leukocyte count.

Table 2 Association between SOX expression and clinical patient features

Assessed parameters	Value	SOX11 expression	P value
Sex	Male	0.1 (0-81.6)	0.797
	Female	0.03 (0-106)
CD34	Negative	0.05 (0-106)	0.607
	Positive	0.105 (0-105)
FLT3 ITD	Negative	0.005 (0-5.9)	P < 0.001
	Positive	0.09 (0-2.4)
NPM	Negative	0.11 (0-105)	0.166
	Positive	0.01 (0-9.5)
Liver	Negative	0.055 (0-106)	0.928
	Positive	0.09 (0-5.8)
Spleen	Negative	0.06 (0-106)	0.599
	Positive	0.05 (0-5.86)
LNs	Negative	0.05 (0-106)	0.953
	Positive	0.21 (0-5.86)
BM celularity	Hypocellular	0.09 (0-2.1)	0.268
	Normocellular	0.03 (0-82.5)
	Hypercellular	0.11 (0-106)
FAB	AML-M1	0.02 (0-106)	0.008
	AML-M2	0.35 (0-105)
	AML-M3	0.115 (0-0.21)
	AML-M4	0.015 (0-10.9)
	AML-M5	0 (0-2.9)
Cytogenetic	Normal	0.01 (0-5.9)	0.011
	Abnormal	0.1 (0-2.4)
CR	Negative	0.055 (0-6.19)	0.806
	Positive	0.145 (0-81.57)
Relapse/refractory	Negative	0.08 (0-10.9)	0.702
	Positive	0.12 (0-81.6)
Death	Negative	0.14 (0-10.9)	0.593
	Positive	0.085 (0-81.6)
Age	SOX low expression	44 (18-70)	0.784
	SOX over expression	43 (18-78)
Hb	SOX low expression	7.2 (2-14)	0.122
	SOX over expression	7.6 (5-14)
PLT	SOX low expression	47.5 (4-836)	0.921
	SOX over expression	46 (8-420)
TLC	SOX low expression	61530 (1150-387900)	0.058
	SOX over expression	30600 (1120-488900)
PB blast	SOX low expression	31 (0-97)	0.206
	SOX over expression	30 (0-97)
BM blast	SOX low expression	50 (0-98)	0.516
	SOX over expression	50 (0-96)
D14 blasts	SOX low expression	0 (0-77)	0.243
	SOX over expression	0 (0-80)
D28 blasts	SOX low expression	0 (0-53)	0.289
	SOX over expression	0 (0-80)

TLC: Total leukocyte count; PLT: Platelet counts; AML: Acute myeloid leukemia; BM: Bone marrow; CR: Complete remission; Hb: Hemoglobin; LNs: Lymph nodes; PB: Peripheral blood.